ECHEMI on-site interview at 85th API China - HEC PHARM

About HEC Pharm: HEC Pharm was established in 2002. Today HEC Pharm includes 4 subsidiaries with manufacturing facilities. They are HEC Pharm Co. Ltd. and Yichang Changjiang Pharmaceutical Co., Ltd. both located in Hubei, China, Sunshine Lake Pharma Co., Ltd. and Ruyuan HEC pharm Co., Ltd. located in Guangdong, China.

After several years development, HEC Pharm has become one of the most innovative and promising pharmaceutical companies in China.

Q: As the only manufacturer of OSELTAMIVIR phosphate granules in the Chinese market, HEC Pharm has many core competitive products. Can you tell usabout the characteristics and innovations of HEC Pharm’s core products?

A: HEC Pharm is mainly based on generic drugs and is based on oseltamivir. A number of generic drugs such as benzbromarone, linagliptintablets, sitagliptin tablets have been approved, and many generic drugs have participated in the domestic market. The company’s centralized procurement andbid, will occupy a place in the domestic preparation market in the future, and the innovative drug imitavir has also been approved, focusing on the domestic hepatitis C treatment field. HEC Pharm will unswervingly follow the path of medical innovation.

Q: The covid-19 has swept the world this year, and it is still in the post-epidemic era. What impact and changes will the epidemic bring to HEC Pharm?

A: In the future, generic drug preparations and macrolide APIs will beused as profit points. The competitiveness of APIs will increase during the epidemic, and some small companies will find it difficult to survive. HEC Pharmwill occupy an indispensable position in the API field. Azithromycin is alsothe focus of our later work as a drug for the adjuvant treatment of novel coronavirus. Our qualifications for this product are very complete. There areno problems with FDA and CEP. The specific row spacing is hard to say at this stage, it is estimated that the price is almost at a high and stable state.

Q: We are concerned that HEC Pharm has a huge sales network in thedomestic market. According to relevant data, the export of my country's medicaland healthcare products in 2019 was also the highest level in the past 8 years.So what is the current status of HEC Pharm related products in export andforeign markets? Are there any plans for export and foreign market layout inthe future?

A: We mainly focus on domestic preparations, supplemented by foreignpreparations. In line with the background of internal circulation. API exportsmay increase the layout of non-regulated markets.

Q: The current autumn and winter flu season is coming soon, can you share with us the market and product trends in the field of anti-flu virus?

A: Since it is still in the epidemic stage, everyone develops a good habit of wearing masks, which has an inhibitory effect on the spread of influenza virus. However, autumn and winter are the influenza epidemic seasons, and the anti-influenza virus market sales trend will still gradually rise.